Project Grant R13HL158206
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $760,083 to the University of Colorado-Denver under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion expected by May 31, 2029. This research initiative investigates the mechanisms underlying trauma-induced coagulopathy (TIC) and thromboinflammation, with a focus on the protein C system's dual role in both driving coagulopathy and...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $783,715 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through June 30, 2029. The project, titled "Criteria for Retriage to Improve Trauma Induced Coagulopathy and Hemorrhage Associated Lethality," will develop evidence-based clinical guidelines and decision-support tools...
- Federal Grant Award Summary The Johns Hopkins University received a Cooperative Agreement award of $958,886 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for June 30, 2030. The award funds the establishment of a Rare Disease Clinical Research Consortium (RDCRC) designated the IMPACT Study to create a collaborative clinical and translational research infrastructure...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $454,336 Project Grant award, effective September 1, 2025, through June 30, 2029, under the Biomedical Research and Research Training program (CFDA 93.859) administered by the National Institute of General Medical Sciences. The award funds a four-year research initiative investigating the fibrinolytic-inflammatory axis in severe trauma outcomes, specifically examining how innate immune cell dysfunction...
- Grant Award Summary New York University received a $272,226 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2027. The award funds a novel secondary data analysis examining how clinician and scheduling characteristics across interprofessional intensive care unit (ICU) teams impact patient outcomes for mechanically ventilated adults. The research utilizes...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vanderbilt University Medical Center a $185,720 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective September 1, 2025, through August 31, 2030, to conduct a randomized clinical trial investigating sedation-only intubation protocols for emergency tracheal intubation in critically ill adults. The research project, led by Dr. Stephanie DeMasi in the Department of Emergency Medicine, will...
- This $500,000 Project Grant award from the U.S. Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program supports research to improve understanding of delayed diagnosis of venous thromboembolism (VTE) in ambulatory care settings. The project aims to leverage electronic health record (EHR) data and stakeholder expertise to identify risk factors, disparities, and outcomes associated with delayed and missed VTE diagnosis in...
- Federal Cooperative Agreement Summary Brigham & Women's Hospital Inc., through the Department of Faulkner Pathology, received a Cooperative Agreement award of $862,130 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2032. The award supports the STATINS TO PREVENT CANCER ASSOCIATED VENOUS THROMBOEMBOLISM (STAT-CAT) trial, a randomized clinical trial investigating whether...
- Federal Grant Award Summary Vitalant Research Institute received a $262,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for August 31, 2027. The research initiative investigates the genetic and molecular drivers of mitochondrial DNA (mtDNA) levels in blood components and their potential role in transfusion-related acute lung injury. The...
- Federal Cooperative Agreement Summary The University of Alabama at Birmingham received a $318,167 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, through August 31, 2032. This award supports the WARRIORS Trial (Women's Aneurysm Research: Repair Immediately or Routine Surveillance), an international randomized controlled trial designed to establish sex-specific...
2021 CONSENSUS CONFERENCE TO IMPLEMENT OPTIMAL VTE PROPHYLAXIS IN TRAUMA - PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR (LAST, FIRST, MIDDLE): COSTANTINI, TODD W & HAUT, ELLIOTT R THE PROPOSED 2021 CONSENSUS CONFERENCE TO IMPLEMENT OPTIMAL VTE PROPHYLAXIS IN TRAUMA WILL CONVENE A MULTIDISCIPLINARY GROUP OF ESTABLISHED AND JUNIOR SCIENTISTS AND PRACTITIONERS IN AN INTERACTIVE FORUM (IN-PERSON AND ONLINE) DURING WHICH THE CURRENT STATE AND FUTURE OF THE SCIENCE ON VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS WILL BE PRESENTED. VTE, WHICH INCLUDES BOTH DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE), IS A SIGNIFICANT CAUSE OF MORBIDITY AND MORTALITY FOR PATIENTS FOLLOWING MAJOR TRAUMA. IMPROVING PATIENT OUTCOMES BY DECREASING VTE RATES IN TRAUMA PATIENTS WILL REQUIRE IMPLEMENTATION OF EVIDENCE-BASED RECOMMENDATIONS, OPTIMIZATION OF CURRENT CARE PATHWAYS, AND DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PHARMACOLOGIC PROPHYLAXIS IN THE FUTURE. THE CONFERENCE PRIMARY OBJECTIVES ARE TO PROMOTE RESEARCH RELATED TO DELIVERING TIMELY PHARMACOLOGIC VTE PROPHYLAXIS, TO SUPPORT THE DEVELOPMENT OF EDUCATION PLATFORMS AND CLINICAL CARE PATHWAYS TO IMPROVE IMPLEMENTATION OF CURRENT GUIDELINES, AND TO DEVELOP FUTURE RESEARCH OBJECTIVES FOR VTE PROPHYLAXIS IN TRAUMA. THE CONFERENCE AIMS ARE TO: 1) DEFINE GUIDELINES FOR VTE PROPHYLAXIS IN HIGH-RISK TRAUMA PATIENTS THAT ARE ACCEPTED BY TRAUMA CLINICIANS, SURGICAL SUBSPECIALISTS, NURSES, PHARMACISTS, AND ALL SPECIALISTS WHO PROVIDE CARE TO INJURED PATIENTS; 2) DISSEMINATE THESE GUIDELINES TO RESPECTIVE SPECIALTY ORGANIZATIONS; 3) ADDRESS CHALLENGES TO THE DISSEMINATION AND IMPLEMENTATION OF THESE GUIDELINES ACROSS HEALTHCARE SYSTEMS; 4) DEFINE RESEARCH PRIORITIES TO MEASURE SHORT- AND LONG-TERM OUTCOMES FOR INJURED PATIENTS AT RISK FOR VTE, STUDY THE IMPLEMENTATION OF CONSENSUS GUIDELINES, AND INVESTIGATE NOVEL PHARMACOLOGIC APPROACHES TO VTE PROPHYLAXIS; 5) INTEGRATE THE VOICE OF INJURED PATIENTS AND PEOPLE WITH VTE TO PROMOTE TRULY PATIENT-CENTERED CARE RESEARCH; 6) PROVIDE AN OPPORTUNITY TO ENGAGE JUNIOR INVESTIGATORS, WOMEN, AND UNDERREPRESENTED MINORITIES INTERESTED IN TRAUMA AND VTE TO ENSURE THE PIPELINE OF A DIVERSE GROUP OF INVESTIGATORS AND SPUR NEW GRANT APPLICATIONS. TO ENCOURAGE ATTENDANCE BY JUNIOR INVESTIGATORS AND TRAINEES, 5 JUNIOR INVESTIGATOR TRAVEL AWARDS WILL BE MADE TO COVER TRAVEL AND REGISTRATION EXPENSES. THE OFFERING OF THESE AWARDS WILL BE ANNOUNCED THROUGH THE COALITION FOR NATIONAL TRAUMA RESEARCH'S MEMBER ORGANIZATIONS (TO THEIR MORE THAN 14,000 MEMBERS) AND RELATED PROFESSIONAL ORGANIZATIONS COMPRISING UNDERREPRESENTED SCIENTISTS AND PRACTITIONERS. AWARDEES WILL BE ENCOURAGED TO PARTICIPATE AS AUTHORS IN THE PREPARATION OF THE CONFERENCE PROCEEDINGS FOR PUBLICATION. ROUNDTABLE DISCUSSIONS AND NETWORKING ACTIVITIES ARE INCLUDED IN THE CONFERENCE AGENDA TO FACILITATE INTERACTION BETWEEN JUNIOR AND SENIOR PARTICIPANTS. THE CONFERENCE WILL ALIGN WITH NHLBI'S OVERARCHING STRATEGIC VISION TO: "DEVELOP AND OPTIMIZE NOVEL DIAGNOSTIC AND THERAPEUTIC STRATEGIES TO PREVENT, TREAT, AND CURE HLBS DISEASES" (OBJ. 5), TO "OPTIMIZE CLINICAL AND IMPLEMENTATION RESEARCH TO IMPROVE HEALTH AND REDUCE DISEASE" (OBJ. 6), AND TO "FURTHER DEVELOP, DIVERSIFY, AND SUSTAIN A SCIENTIFIC WORKFORCE CAPABLE OF ACCOMPLISHING THE NHLBI'S MISSION" (OBJ. 7). OMB NO. 0925-0001/0002 (REV. 03/2020 APPR TO 02/28/2023) PAGE 1 CONTINUATION FORMAT PAGE
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/12/22 | ||
| Not listed | $0 | 8/12/22 | ||
| Not listed | $20.0k | 6/22/21 | ||
| Not listed | $20.0k | 6/22/21 | ||
| Not listed | $20.0k | 6/22/21 |